Shots: Finch and Takeda will leverage Finch’s platform to develop microbiome-based therapeutics targeting Crohn’s disease. Takeda to get exclusive worldwide rights to commercialize rationally selected microbiota (RSM) therapies developed for […]readmore
Shots: The FDA’s BT designation follows P-II PRISM3 study results assessing CP101 vs PBO in patients with recurrent C. difficile FDA’s BT designation is granted to the drugs showing clinical […]readmore
Copyright © 2020 Digiqole. All Right Reserved.